LFSCF/m Emerald Life Sciences Innovation ETF

Grow my money1y track recordRanked #1,959 of 2,960 in this goal

Seeks long-term capital appreciation.

By Emerald Mutual Fund Advisers Trust · Launched 2024

Annual Cost

0.54%

#2,755 of 5,562 · average

Fund Size

$105M

#2,886 of 5,562 · mid-size

Return (1Y)Goal

+72.0%

Track Record

1 year

#3,913 of 5,562 · young

Performance

Total-return NAV · USD

Growth of $10,000

$17,195+72.0%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Active selection

Sector

Health care

Focus

Biotech & Genomics

What it actually holds

By weight

Concentration

Top 10 holdings = 50.9% of fundmoderately concentrated

Cogent Biosciences Inc

10.0%

LivaNova PLC

6.4%

Travere Therapeutics Inc

5.3%

Guardant Health Inc

5.3%

TransMedics Group Inc

5.1%

Madrigal Pharmaceuticals Inc

4.3%

Savara Inc

4.1%

Bridgebio Pharma Inc

4.0%

Nektar Therapeutics

3.3%

KalVista Pharmaceuticals Inc

3.3%

Asset allocation

Stocks

99.0%

Bonds

0.8%

Cash

0.3%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

26.5%High

Year-on-year price swings

Max drawdown

-29.7%Moderate

Worst peak-to-trough loss

Sharpe (3Y)

Unavailable

Needs 3+ years of history

Sortino (3Y)

Not yet

Needs 3+ years of history

Where to buy

Listing

Exchange: NASDAQ Global Select Market

Full fund details

Objective: Seeks long-term capital appreciation.
Strategy: Actively managed ETF investing primarily in equity securities of innovative life science companies. Focuses on growth opportunities in biotechnology, pharmaceuticals, medical devices, and healthcare services.
Inception date: October 30, 2024
Fund family: Emerald Mutual Fund Advisers Trust